Neogen Corp CEO Mikheal Nassif Executes RSU Tax Withholding on August 19, 2026
Mikheal Nassif, CEO and Director of Neogen Corp, had 20,397 restricted stock units (RSUs) withheld on August 19, 2026, to cover tax obligations upon vesting. This transaction, detailed in a Form 4 filing, involved shares valued at $11.87 each. Following the tax withholding, Nassif retains ownership of 25,655 restricted stock units.
Neogen Corp (NEOG) CAO has stock withheld to cover RSU taxes
Neogen Corp's Chief Accounting Officer, John Patrick Moylan, had 2,365 shares of NEOG common stock withheld to cover tax liabilities when restricted stock units (RSUs) vested on August 19, 2026. This transaction, valued at $11.87 per share for tax purposes, resulted in Moylan directly holding 29,331 shares afterward. The event is categorized as a tax-withholding disposition rather than an open-market sale.
Neogen (NEOG) CEO uses 20K shares to cover RSU taxes
Neogen CEO Mikheal Nassif had 20,397 shares of common stock withheld on August 19, 2026, to cover tax obligations related to vested Restricted Stock Units (RSUs). This transaction, valued at $11.87 per share, was an F-code transaction for tax withholding and not an open-market sale. Following this, Nassif directly holds 25,655 shares of NEOGEN common stock.
Neogen Corporation (NASDAQ:NEOG) Given Average Rating of "Hold" by Brokerages
Neogen Corporation (NASDAQ:NEOG) has received a consensus "Hold" rating from five research firms, with an average 1-year price target of $11.6667. The company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Institutional investors have also been adjusting their positions in Neogen stock.
NEOGEN CORP (NEOG) grants CAO stock options and RSUs in new equity awards
NEOGEN CORP's Chief Accounting Officer, John Patrick Moylan, received new equity awards on August 14, 2026. These awards include options to purchase 18,693 shares of common stock at an exercise price of $11.65, expiring in 2036, and 8,584 restricted stock units (RSUs). Both the options and RSUs will vest in equal annual installments over three years.
Neogen Corp (NEOG) grants 196,276 options and 38,627 PSUs to Chief Legal Officer
Neogen Corp (NEOG) has granted its Chief Legal Officer, Stacey Jennifer Evans, equity compensation awards. These awards include options to acquire 196,276 shares of common stock at an exercise price of $11.65 per share, vesting over three years, and 38,627 performance stock units (PSUs) that will vest entirely after a three-year period. The grants were reported on August 14, 2026, and are directly owned by the officer.
Neogen Corp (NEOG) grants CFO 261,702 options and 51,502 PSUs in equity awards
Neogen Corp (NEOG) has granted its CFO, Richard Bryan Riggsbee, equity awards consisting of 261,702 stock options and 51,502 Performance Share Units (PSUs). The options have an exercise price of $11.65 per share and vest in equal annual installments over three years, while the PSUs also valued at $11.65 per share, vest in full at the end of the three-year anniversary of the grant date. Both awards were reported on August 14, 2026, and are directly owned by the CFO.
NEOGEN CORP (NEOG) CEO awarded 719,679 options and 141,631 PSUs in equity grant
NEOGEN CORP CEO Mikheal Nassif was granted 719,679 stock options with an exercise price of $11.65 and 141,631 performance stock units (PSUs) on August 14, 2026. The stock options vest in equal annual installments over three years, while the PSUs vest entirely on the three-year anniversary of the grant. Following these awards, Nassif directly holds 141,631 common shares and option-based rights for 719,679 shares.
Bank of America Corp DE Has $43.11 Million Stake in Neogen Corporation $NEOG
Bank of America Corp DE has reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 14.2% in the first quarter, selling 770,275 shares but still retaining 4.64 million shares valued at approximately $43.11 million. Institutional investors collectively own 96.73% of Neogen. The company recently surpassed quarterly earnings and revenue estimates and holds a consensus "Hold" rating from analysts with an average target price of $11.67.
Neogen Corporation (NEOG) Stock Price, News, Quote & History
Neogen Corporation (NEOG) stock closed at $11.49, up 0.79% on August 11, 2026, with an after-hours price of $11.55. The company specializes in food and animal safety products and has shown significant year-to-date and one-year returns of 64.38% and 124.85% respectively. Analysts have an average target price of $13.00, with Piper Sandler recently reiterating a Neutral rating and raising the price target from $11 to $13.
Neogen Corporation (NEOG) Stock Forecasts
Argus has raised its target price for Neogen Corporation (NEOG) to $12.00, citing the company's focus on food and animal safety products. Neogen, based in Lansing, Michigan, develops, manufactures, and markets these products. The report provides a summary of the company and suggests upgrading for more detailed research and trade insights.
Neogen CEO Mikheal Nassif buys $4,369 in company stock By Investing.com
Neogen CEO Mikheal Nassif purchased 370 shares of NEOGEN CORP (NASDAQ:NEOG) common stock for $4,369, priced at $11.81 per share. This transaction follows a significant 139% gain in NEOGEN's stock over the past year, though InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong fiscal fourth-quarter results, exceeding revenue and earnings expectations, indicating robust financial health.
Neogen Corp (NASDAQ: NEOG) CEO notes son's indirect buy of 370 shares
Neogen Corp CEO Mikheal Nassif reported an indirect purchase of 370 shares of Common Stock at $11.81 per share on August 4, 2026. The shares are held by his son, bringing the reported indirect holdings to 1,074 shares, though Nassif disclaims beneficial ownership. This transaction was filed via a Form 4, detailing the family's stock purchase.
Neogen CEO Mikheal Nassif buys $4,369 in company stock
Mikheal Nassif, CEO of NEOGEN CORP (NASDAQ:NEOG), recently purchased 370 shares of company stock for $4,369, increasing his indirect beneficial ownership to 1,074 shares held by his son. This transaction follows Neogen's strong fiscal fourth-quarter performance, which exceeded revenue and earnings estimates, contributing to a 139% stock gain over the past year. Despite the positive financial news, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value.
Arrowstreet Capital Limited Partnership Buys New Position in Neogen Corporation $NEOG
Arrowstreet Capital Limited Partnership has acquired a new stake in Neogen Corporation, purchasing 320,808 shares valued at approximately $2.98 million, increasing institutional ownership to 96.73%. This move comes as analyst sentiment for Neogen is mixed, with a consensus "Hold" rating and a target price of $11.67, despite the company recently beating quarterly earnings and revenue estimates.
NEOG Reiterated by Piper Sandler -- Price Target Raised to $13.0
Piper Sandler has reiterated a "Neutral" rating for Neogen (NEOG) and increased its price target from $11.00 to $13.00, reflecting cautious optimism despite the stock appearing overvalued according to GuruFocus's GF Value. Neogen, a company focused on food and animal safety, shows fair overall performance with strengths in profitability and valuation, but weaknesses in growth and financial strength. Insider activity has been neutral, with no buying or selling in the last three months, and guru investors show mixed sentiment.
Neogen Corp reports results for the quarter ended May 31 - Earnings Summary
Neogen Corp has reported its earnings results for the quarter that ended on May 31. The article provides an earnings summary from Reuters, accessible to TradingView users with unlimited access. The full article content requires a subscription to view.
NEOGEN CORP FY 2026: Revenue $870.4M, Net loss $7.9M, EPS $(0.04) — 10-K Summary
NEOGEN CORP reported its fiscal year 2026 results, with revenue reaching $870.4 million and a net loss of $7.9 million, resulting in a diluted loss per share of $(0.04). While revenue decreased by 3% from the prior year, the company significantly narrowed its net loss compared to FY2025. Strategic actions included a divestiture, internal manufacturing transitions, and a planned headcount reduction, alongside improvements in operational efficiency and sales momentum in key product areas.
Neogen (NASDAQ:NEOG) Posts Earnings Results, Beats Expectations By $0.04 EPS
Neogen (NASDAQ:NEOG) reported strong quarterly earnings, beating analyst expectations with an EPS of $0.09 against a consensus of $0.05 and revenue of $225.3 million compared to estimates of $212.35 million. Despite flat year-over-year revenue, the company provided an optimistic fiscal 2027 outlook, projecting revenues of $880 million–$885 million and adjusted EBITDA of $180 million–$182 million. Shares surged 22.7% following the announcement, driven by accelerating food-safety growth, recovery in animal safety, and strategic investments in R&D and debt reduction.
Neogen (NEOG) Stock Climbs As Margin Repair Counters Lingering Losses
Neogen (NEOG) stock climbed after the company reported fourth-quarter earnings showing significant margin repair, with adjusted EBITDA margins reaching over 20%. While the company still reported a net loss of US$11.3 million, this was a material reduction from the previous year, and revenue remained broadly flat. The market is reacting positively to operational improvements and better cash generation, despite lingering concerns about future profitability and integration challenges.
Neogen Corporation $NEOG Position Boosted by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Neogen Corporation by 23.4% in the first quarter, now holding 9.13 million shares. This comes as Neogen exceeded fiscal fourth-quarter earnings and revenue expectations, and provided an above-consensus fiscal 2027 outlook, despite flat year-over-year revenue and projected higher R&D spending. Institutional investors collectively own 96.73% of the company, which maintains a consensus "Hold" rating from analysts.
Neogen (NASDAQ:NEOG) Hits New 12-Month High After Earnings Beat
Neogen (NASDAQ:NEOG) shares surged to a new 52-week high after the company reported fiscal Q4 earnings of $0.09 per share, beating the consensus estimate of $0.05, and revenue of $225.3 million, exceeding estimates of $212.35 million. Management also provided an optimistic fiscal 2027 outlook, forecasting revenue between $880 million and $885 million and adjusted EBITDA of $180 million to $182 million. Despite increased R&D spending plans potentially limiting near-term profitability, the strong earnings beat and forward guidance drove the stock's positive reaction.
Neogen posts strongest food safety unit growth since 2023 in Q4
Neogen Corp. reported its strongest food safety unit growth in three years during Q4 fiscal 2026, with core food safety revenue growing 5.8%, driven by gains in pathogen testing, culture media, and bacterial sanitation products. Despite this, overall company revenue remained flat and the company posted a net loss of $11.3 million. Neogen guided toward $880-885 million revenue for fiscal 2027 and plans to transition Petrifilm manufacturing to its Lansing site.
Neogen Corporation stock hits 52-week high at 11.45 USD
Neogen Corporation (NEOG) reached a new 52-week high of $11.45, with its stock currently trading at $11.46. The food safety company has a market capitalization of approximately $2.48 billion and has seen a 143.87% increase over the past year. Despite strong performance and better-than-expected Q4 2026 financial results, InvestingPro analysis suggests the stock might be overvalued.
Neogen (NASDAQ:NEOG) Shares Gap Up - What's Next?
Neogen (NASDAQ: NEOG) shares gapped up by 13.5% prior to trading, opening at $10.50 after closing at $9.40, with trading volume reaching 323,123 shares. The company has a consensus "Hold" rating and a $10.67 price target from analysts, despite mixed sentiment. Institutional ownership is high at 96.73%, with a number of firms increasing or establishing new positions in the animal-safety products company.
Earnings call transcript: Neogen tops Q4 2026 estimates as shares jump 10%
Neogen Corporation reported stronger-than-expected fiscal fourth-quarter results for 2026, surpassing Wall Street estimates for both earnings and revenue, which led to a 10.43% jump in premarket shares. The company highlighted improved core growth across its food safety and animal safety segments, the highest food safety growth since 2023, and increased profitability with adjusted EBITDA rising 12% year-over-year. Neogen plans significant investments in fiscal 2027, including a 50% increase in R&D spending and transformation initiatives, as it shifts from stabilization to a focus on profitable growth and market leadership in food safety.
Neogen Q4 FY26 slides: food safety growth hits 3-year high
Neogen Corporation reported its strongest quarterly performance since its 2023 3M food safety acquisition, with core revenue growing 4.3% and food safety sales increasing by 5.8%, a three-year high. The company outlined a strategic shift towards sustainable growth through enhanced commercial operations, a 50% increase in R&D spending, and efficiency improvements like the Petrifilm manufacturing transition. Neogen also provided fiscal 2027 guidance expecting 3% core revenue growth and improved adjusted EBITDA, with plans to use proceeds from a Genomics divestiture for debt reduction.
Neogen Food Safety Core Growth Hits 5.8%, Highest Since FY23
Neogen Corporation reported Q4 FY26 revenue of $225.3 million, with Food Safety core growth at 5.8%, the highest since FY23. The company also provided FY27 guidance, projecting revenues between $880 million and $885 million, and adjusted EBITDA of $180 million to $182 million. Neogen is on track to transition Petrifilm manufacturing and is working to divest its Genomics business by the first half of FY27.
Neogen (NEOG) Beats Q4 Earnings and Revenue Estimates
Neogen (NEOG) reported Q4 earnings of $0.09 per share, significantly exceeding the Zacks Consensus Estimate of $0.05 per share, and also surpassed revenue estimates with $225.3 million. The company has consistently beaten revenue estimates over the last four quarters and has outperformed the S&P 500 this year, though its current Zacks Rank is #3 (Hold). The medical testing kits maker's stock performance and future outlook will largely depend on management's comments and evolving earnings estimates.
Neogen: Fiscal Q4 Earnings Snapshot
Neogen Corp. reported a fiscal fourth-quarter loss of $11.3 million, or 5 cents per share, which beat Wall Street expectations after adjustments. The medical testing kit maker posted revenue of $225.3 million for the quarter, also exceeding forecasts. For the full year, Neogen reported a loss of $7.9 million on revenues of $870.4 million and provided revenue guidance for the current quarter and full year.
American Capital Management Inc. Trims Stock Position in Neogen Corporation $NEOG
American Capital Management Inc. significantly reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 90.4% in the first quarter, selling over 1.2 million shares. Despite this, other institutional investors like JPMorgan Chase & Co. and Bessemer Group Inc. increased their holdings, with institutional investors now owning 96.73% of the company. Neogen's stock recently opened at $9.34, with an average analyst rating of "Hold" and a price target of $10.67.
Neogen Corp (NEOG) Cash Flow
This article provides a detailed historical cash flow statement for Neogen Corp (NEOG), including operating, investing, and financing cash flows, presented quarterly and annually. It outlines key cash flow metrics such as net income, operating gains/losses, deferred tax, changes in working capital, capital expenditures, and free cash flow. The data spans several fiscal years, offering a comprehensive look into the company's financial health and cash generation capabilities.
Neogen Corp (NEOG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an historical overview of dividends and stock splits for Neogen Corp (NEOG). It notes that Neogen has not distributed any dividends in the past five years. The company has had one recorded stock split event, a 1-for-2 split on May 12, 2021.
Healthcare of Ontario Pension Plan Trust Fund Sells 193,454 Shares of Neogen Corporation $NEOG
The Healthcare of Ontario Pension Plan Trust Fund reduced its stake in Neogen Corporation by 5.5% in the first quarter, selling 193,454 shares and now owning 3,297,346 shares valued at $30.63 million. Despite this, other institutional investors like Huntington National Bank and ProShare Advisors LLC increased their holdings in Neogen. The company's stock currently trades at $9.40, with a market cap of $2.05 billion, and has an average analyst rating of "Hold" with a consensus target price of $10.67.
Granahan Investment Management LLC Makes New Investment in Neogen Corporation $NEOG
Granahan Investment Management LLC has made a new investment in Neogen Corporation, acquiring 250,026 shares valued at approximately $2.3 million during the first quarter. This makes Granahan the owner of about 0.11% of Neogen's stock, with other major institutional investors like AQR Capital and Goldman Sachs also increasing their holdings. Analysts maintain a mixed but cautious outlook on Neogen, with an average "Hold" rating and a target price of $10.67, as the stock recently traded at $9.40.
Neogen Corporation (NASDAQ:NEOG) Receives Average Rating of "Hold" from Brokerages
Neogen Corporation (NASDAQ:NEOG) has an average "Hold" rating from six brokerages, with one analyst issuing a sell rating, three a hold, and two a buy, and an average 12-month price target of $10.6667. Recent analyst reports include an upgrade from "hold" to "buy" by Wall Street Zen and a downgrade from Weiss Ratings. Institutional investors hold 96.73% of the stock, with several hedge funds increasing their positions in recent quarters.
NEOG|Neogen Corp|Price:9.400|Chg%:-0.210
This article provides a comprehensive financial overview of Neogen Corp (NEOG), including its stock price, market capitalization, and various financial statements. It details the company's income statement, balance sheet, and cash flow statement on a quarterly and annual basis. The report also highlights key financial indicators like EPS, revenue, net profit, margins, and debt-to-assets ratio, along with FAQs based on the FY2025 earnings report.
NEOG|Neogen Corp|Price:9.400|Chg%:-0.210
This article provides a comprehensive stock analysis of Neogen Corp (NEOG) from TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It details the company's scores across financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment, alongside key insights and analyst ratings. The analysis notes significant institutional ownership and an expected stable short-term price trend.
Neogen Corp (NEOG) Valuation: PE, PB & Fair Value Analysis
Neogen Corp (NEOG) currently holds a valuation score of 7.95, placing it 121 out of 200 in the Healthcare Equipment & Supplies industry. Its P/E ratio is -3.35, significantly below its recent high and above its recent low. However, P/B, P/S, and P/CF data have not yet been disclosed by the company.
Neogen Corp (NEOG) Institutional Confidence
Neogen Corp (NEOG) has a strong institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional holdings have increased by 6.66% quarter-over-quarter, with Ron Baron being the largest institutional shareholder. Several major institutional investors show varying activity, such as T. Rowe Price Investment Management significantly increasing its holdings.
Clarkston Capital Partners LLC Has $20.48 Million Holdings in Neogen Corporation $NEOG
Clarkston Capital Partners LLC significantly reduced its stake in Neogen Corporation (NASDAQ:NEOG) by 80.5% in the first quarter, selling over 9.1 million shares but retaining 2.2 million shares valued at approximately $20.48 million. Despite this reduction, institutional investors collectively hold 96.73% of Neogen shares, with several firms like Dimensional Fund Advisors and T. Rowe Price recently increasing their positions. Neogen's stock performance shows a 50-day simple moving average of $9.25 and a 200-day simple moving average of $9.55, with analysts holding a "Hold" consensus and an average price target of $10.67.
Analysts Conflicted on These Healthcare Names: Cardinal Health (CAH) and Neogen (NEOG)
Analysts have issued conflicting reports on two healthcare companies, Cardinal Health (CAH) and Neogen (NEOG). Bank of America Securities maintained a Buy rating on Cardinal Health with a $260.00 price target, while William Blair analyst Brandon Vazquez maintained a Hold rating on Neogen. Both companies operate within the Healthcare sector and have received significant coverage from analysts.
Neogen (NEOG) Expected to Post Earnings on Thursday
Neogen (NASDAQ:NEOG) is expected to announce its Q4 2026 earnings before the market opens on Thursday, July 30th. Analysts project earnings of $0.05 per share and revenue of $212.35 million. The company's stock has an average "Hold" rating from analysts with an average price target of $10.67.
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH) and Neogen (NEOG)
This article provides analyst insights on two healthcare companies: Cardinal Health (CAH) and Neogen (NEOG). Bank of America Securities maintained a Buy rating on Cardinal Health with a $260.00 price target, while William Blair maintained a Hold rating on Neogen. The article details analyst ratings, price targets, and performance metrics for both companies.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardinal Health (CAH) and Neogen (NEOG)
Analysts have mixed opinions on two healthcare stocks: Cardinal Health (CAH) and Neogen (NEOG). Cardinal Health received a Strong Buy consensus, with Bank of America Securities maintaining a Buy rating and TipRanks – Google upgrading it to Buy. Neogen, however, received a Moderate Buy consensus with a Hold rating from William Blair.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG) and Cardinal Health (CAH)
Analysts have issued mixed ratings for two healthcare stocks: Neogen (NEOG) and Cardinal Health (CAH). William Blair maintained a Hold rating on Neogen, which is trading near its 52-week low. Bank of America Securities, however, maintained a Buy rating on Cardinal Health, citing an 11.4% upside and a "Strong Buy" consensus.
Illinois Municipal Retirement Fund Invests $1.17 Million in Neogen Corporation $NEOG
The Illinois Municipal Retirement Fund (IMRF) recently invested $1.17 million in Neogen Corporation (NASDAQ:NEOG) by purchasing 126,139 shares during the first quarter. This comes as institutional and hedge fund ownership of Neogen stands at 96.73%, with other major investors also adjusting their stakes. Analysts currently have a "Hold" consensus rating on Neogen with an average price target of $10.67, while the stock last traded at $9.83.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG) and Cardinal Health (CAH)
The article discusses mixed analyst opinions on two healthcare stocks: Neogen (NEOG) and Cardinal Health (CAH). A William Blair analyst maintained a Hold rating on Neogen, while a Bank of America Securities analyst maintained a Buy rating on Cardinal Health with a $260.00 price target. The consensus for Neogen is a Moderate Buy, and for Cardinal Health, it's a Strong Buy.
Analysts Offer Insights on Healthcare Companies: Neogen (NEOG) and Cardinal Health (CAH)
Analysts have provided insights on two healthcare companies: Neogen (NEOG) and Cardinal Health (CAH). William Blair analyst Brandon Vazquez maintained a Hold rating on Neogen, while Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health with a $260.00 price target. The Street generally suggests a Moderate Buy for Neogen and a Strong Buy for Cardinal Health.
Neogen (NEOG) to Release Q4 2026 Financial Results on July 30
Neogen Corporation (NEOG) is set to release its Q4 and full fiscal year 2026 financial results on July 30, with analysts projecting revenues between $150M-$155M for Q4 and around $590M for the full year. GuruFocus assesses NEOG as 16.8% undervalued with a GF Value of $12.29 compared to its current price of $10.22, and a GF Score of 69/100, highlighting strengths in valuation and momentum despite lower growth. Investors will be focused on demand recovery in food supply chain testing and synergies from the 3M acquisition.
